Delivery Order SPE2DB20D3101-SPE2DB22FJ9A2

Award Date 5/23/22
Potential Completion Date 5/24/22
Potential Value $7K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,691.88, is for the delivery of Xifaxan 550 mg tablets. This is a Delivery Order contract with a Firm Fixed Price pricing type, with a completion date of December 6, 2023. The contract is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to supply the drug Xifaxan 550 mg tablets. The delivery order has a firm fixed price of $2,666.97 and a completion date of June 6, 2024. This award is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00 through December 31, 2025, which enables the DLA to efficiently...
This federal contract award, valued at $12,938.26, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Xifaxan 550 mg tablets. The award is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,381.71, is for the delivery of Xifaxan 550 mg tablets. This is a firm fixed-price delivery order contract with an ultimate completion date of October 19, 2023. The contract is not designated with any set-aside requirements, indicating open competition. Amerisourcebergen Drug Corp is a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,658.63, is for the delivery of Xifaxan 550 mg tablets. The award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen's parent company, Cencora, Inc., and the DLA Troop Support Medical, valued at up to $999,999,999.00. This IDC serves as the primary vehicle for...
This federal contract award is to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of the drug Xifaxan 550 mg tablets to the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $11,460.87, is a delivery order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that is worth up to $999,999,999 and runs through December 2025. This IDC enables the DLA to efficiently procure a comprehensive range of medical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Xifaxan 550 mg tablets. The $1,992.03 Firm Fixed Price delivery order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen's parent company, Cencora, Inc., and the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for Cencora, Inc. to...
This federal contract award is for the delivery of Xifaxan 550 mg tablets, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract, valued at $7,540.81, was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract is a Delivery Order with a Firm Fixed Price pricing type, and has an ultimate completion date of January 29, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC)...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Xifaxan 550 mg tablets. The $7,918.17 firm fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen's parent company, Cencora, Inc., holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle for Amerisourcebergen to provide a...
This federal contract award is for the delivery of Xifaxan 550 mg tablets to the Defense Logistics Agency (DLA) Troop Support Medical. The contract, with a ceiling value of $6,462.08, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. Amerisourcebergen is a subsidiary of the parent company Cencora, Inc., which also does business as Amerisourcebergen. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the...
  • SPE2DB20D3101
    Indefinite Delivery Contract
  • SPE2DB20D3101-SPE2DB22FJ9A2
    Delivery Order

This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Xifaxan 550 mg tablets. The contract, valued at $7,042.55, is a firm fixed-price delivery order with a completion date of May 24, 2022. This award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 2025. The IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This specific award does not have a set-aside designation, indicating open competition.

Generated 2/27/25, 1:14 PM